416 related articles for article (PubMed ID: 23065000)
1. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.
Robertson JF; Lindemann JP; Llombart-Cussac A; Rolski J; Feltl D; Dewar J; Emerson L; Dean A; Ellis MJ
Breast Cancer Res Treat; 2012 Nov; 136(2):503-11. PubMed ID: 23065000
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta-analysis of randomized controlled trials.
Gong DD; Man CF; Xu J; Fan Y
Asian Pac J Cancer Prev; 2014; 15(5):2095-100. PubMed ID: 24716940
[TBL] [Abstract][Full Text] [Related]
3. Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Ellis MJ; Llombart-Cussac A; Feltl D; Dewar JA; Jasiówka M; Hewson N; Rukazenkov Y; Robertson JF
J Clin Oncol; 2015 Nov; 33(32):3781-7. PubMed ID: 26371134
[TBL] [Abstract][Full Text] [Related]
4. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.
Johnston SR; Kilburn LS; Ellis P; Dodwell D; Cameron D; Hayward L; Im YH; Braybrooke JP; Brunt AM; Cheung KL; Jyothirmayi R; Robinson A; Wardley AM; Wheatley D; Howell A; Coombes G; Sergenson N; Sin HJ; Folkerd E; Dowsett M; Bliss JM;
Lancet Oncol; 2013 Sep; 14(10):989-98. PubMed ID: 23902874
[TBL] [Abstract][Full Text] [Related]
5. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
Xu B; Jiang Z; Shao Z; Wang J; Feng J; Song S; Chen Z; Gu K; Yu S; Zhang Y; Wang C; Zhang F; Yang J
Cancer Chemother Pharmacol; 2011 Jan; 67(1):223-30. PubMed ID: 20938664
[TBL] [Abstract][Full Text] [Related]
6. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Howell A; Robertson JF; Quaresma Albano J; Aschermannova A; Mauriac L; Kleeberg UR; Vergote I; Erikstein B; Webster A; Morris C
J Clin Oncol; 2002 Aug; 20(16):3396-403. PubMed ID: 12177099
[TBL] [Abstract][Full Text] [Related]
7. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Osborne CK; Pippen J; Jones SE; Parker LM; Ellis M; Come S; Gertler SZ; May JT; Burton G; Dimery I; Webster A; Morris C; Elledge R; Buzdar A
J Clin Oncol; 2002 Aug; 20(16):3386-95. PubMed ID: 12177098
[TBL] [Abstract][Full Text] [Related]
8. Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women.
Vergote I;
Eur J Cancer; 2002 Nov; 38 Suppl 6():S57-8. PubMed ID: 12409076
[No Abstract] [Full Text] [Related]
9. Fulvestrant for hormone-sensitive metastatic breast cancer.
Lee CI; Goodwin A; Wilcken N
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011093. PubMed ID: 28043088
[TBL] [Abstract][Full Text] [Related]
10. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.
Bergh J; Jönsson PE; Lidbrink EK; Trudeau M; Eiermann W; Brattström D; Lindemann JP; Wiklund F; Henriksson R
J Clin Oncol; 2012 Jun; 30(16):1919-25. PubMed ID: 22370325
[TBL] [Abstract][Full Text] [Related]
11. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
[TBL] [Abstract][Full Text] [Related]
12. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ
Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454
[TBL] [Abstract][Full Text] [Related]
13. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.
Robertson JF; Llombart-Cussac A; Rolski J; Feltl D; Dewar J; Macpherson E; Lindemann J; Ellis MJ
J Clin Oncol; 2009 Sep; 27(27):4530-5. PubMed ID: 19704066
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
Carlson RW; O'Neill A; Vidaurre T; Gomez HL; Badve SS; Sledge GW
Breast Cancer Res Treat; 2012 Jun; 133(3):1049-56. PubMed ID: 22418699
[TBL] [Abstract][Full Text] [Related]
15. Combination anastrozole and fulvestrant in metastatic breast cancer.
Mehta RS; Barlow WE; Albain KS; Vandenberg TA; Dakhil SR; Tirumali NR; Lew DL; Hayes DF; Gralow JR; Livingston RB; Hortobagyi GN
N Engl J Med; 2012 Aug; 367(5):435-44. PubMed ID: 22853014
[TBL] [Abstract][Full Text] [Related]
16. A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Ma CX; Sanchez C; Gao F; Crowder R; Naughton M; Pluard T; Creekmore A; Guo Z; Hoog J; Lockhart AC; Doyle A; Erlichman C; Ellis MJ
Clin Cancer Res; 2016 Jun; 22(11):2650-8. PubMed ID: 26783290
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.
Jones SE; Pippen J
Clin Breast Cancer; 2005 Apr; 6 Suppl 1():S9-14. PubMed ID: 15865850
[TBL] [Abstract][Full Text] [Related]
18. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.
Howell A; Pippen J; Elledge RM; Mauriac L; Vergote I; Jones SE; Come SE; Osborne CK; Robertson JF
Cancer; 2005 Jul; 104(2):236-9. PubMed ID: 15937908
[TBL] [Abstract][Full Text] [Related]
19. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
McKeage K; Curran MP; Plosker GL
Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).
Lerebours F; Rivera S; Mouret-Reynier MA; Alran S; Venat-Bouvet L; Kerbrat P; Salmon R; Becette V; Bourgier C; Cherel P; Boussion V; Balleyguier C; Thibault F; Lavau-Denes S; Nabholz JM; Sigal B; Trassard M; Mathieu MC; Martin AL; Lemonnier J; Mouret-Fourme E
Cancer; 2016 Oct; 122(19):3032-40. PubMed ID: 27315583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]